#1 Clinical Trials Search in Europe

Pristinamycin

Pristinamycin, also known by its brand name Pyostacine®, is an antibiotic drug that has been the subject of clinical trials to evaluate its effectiveness in treating various bacterial infections. This article focuses on two significant studies: one comparing Pristinamycin to Amoxicillin in treating community-acquired pneumonia in adults, and another examining its efficacy against tonsillitis caused by Streptococcus in children and young adults. These trials aim to determine if Pristinamycin can be an effective alternative to commonly used antibiotics.

Table of Contents

What is PRISTINAMYCIN?

PRISTINAMYCIN, also known by its brand name Pyostacine®, is an antibiotic medication used to treat various bacterial infections[1]. It belongs to a class of antibiotics called streptogramins, which work by inhibiting bacterial protein synthesis, effectively stopping the growth and spread of bacteria in the body.

Medical Conditions Treated with PRISTINAMYCIN

PRISTINAMYCIN is primarily used to treat two main types of bacterial infections:

  • Community-Acquired Pneumonia: This is a type of lung infection that people can get in everyday life, outside of hospitals or healthcare facilities. PRISTINAMYCIN has been studied for its effectiveness in treating adults with acute community-acquired pneumonia[1].
  • Tonsillitis: This is an inflammation of the tonsils, often caused by bacterial infections. PRISTINAMYCIN has been investigated for treating tonsillitis caused by Group A Streptococcus (GAS) in patients aged 6 to 25 years[2].

Dosage and Administration

The dosage and duration of PRISTINAMYCIN treatment can vary depending on the condition being treated and the patient’s age. Here are some examples from clinical studies:

  • For Community-Acquired Pneumonia in adults:
    • 4 tablets (500 mg each) twice a day for 2 days
    • Then 2 tablets three times a day for 5 to 7 days
    • Total treatment duration: 7 to 9 days[1]
  • For Tonsillitis:
    • In children: 50 mg per kg of body weight per day, divided into 2 doses
    • In adults: 1 gram twice daily
    • Total treatment duration: 4 days[2]

PRISTINAMYCIN is typically administered orally in the form of tablets[1][2].

Comparison with Amoxicillin

Clinical studies have compared PRISTINAMYCIN with another commonly used antibiotic, amoxicillin. These studies aim to determine if PRISTINAMYCIN is as effective as amoxicillin in treating certain bacterial infections. Here are some key points:

  • For Community-Acquired Pneumonia: A study compared PRISTINAMYCIN (taken for 7 to 9 days) with amoxicillin (1 gram three times a day for 7 to 9 days) in adults[1].
  • For Tonsillitis: Another study compared PRISTINAMYCIN (taken for 4 days) with amoxicillin (taken for 6 days) in patients aged 6 to 25 years[2].

These comparisons help doctors understand which antibiotic might be more suitable for different patients and conditions.

Efficacy and Safety

The effectiveness and safety of PRISTINAMYCIN are evaluated through various measures in clinical trials:

  • Clinical Efficacy: This is assessed by the percentage of patients cured, based on clinical symptoms and chest X-rays (for pneumonia)[1].
  • Bacterial Eradication: This measures how well the antibiotic eliminates the bacteria causing the infection[2].
  • Specific Pathogen Efficacy: Some studies focus on how well PRISTINAMYCIN works against specific bacteria, such as pneumococcus (a common cause of pneumonia)[1].
  • Relapse Rates: Researchers monitor how many patients experience a return of symptoms after treatment[1].
  • Mortality Rates: In more severe infections like pneumonia, studies may track patient survival rates[1].

Side Effects and Safety Monitoring

As with all medications, PRISTINAMYCIN may cause side effects. Clinical trials closely monitor patients for any adverse events. Common methods of safety monitoring include:

  • Collecting and following up on adverse events reported by patients[1].
  • Monitoring the proportion of patients who experience side effects[1].
  • Documenting any treatment failures or complications[1].

It’s important to note that the specific side effects and their frequencies are not detailed in the provided clinical trial information. Patients should always consult their healthcare provider for the most up-to-date and personalized information about potential side effects and safety considerations.

Aspect Pneumonia Study Tonsillitis Study
Study Type Phase IV, non-inferiority, randomized, double-blind Phase III, open, randomized
Condition Acute community-acquired pneumonia Tonsillitis caused by Group A Streptococcus
Age Group Adults 6 to 25 years old
Pristinamycin Dosage 2g x 2/day for 2 days, then 1g x 3/day for 5-7 days Children: 50 mg/kg/day in 2 doses; Adults: 1g twice daily for 4 days
Comparison Drug Amoxicillin 1g x 3/day for 7-9 days Amoxicillin 50 mg/kg/day in 2 doses (children), 1g twice daily (adults) for 6 days
Primary Outcome Percentage of patients cured (clinical and radiological) Bacterial eradication
Study Duration 1 month per patient Not explicitly stated (final assessment at 10-14 days)

FAQ

  • What is Pristinamycin used for in these clinical trials? In these trials, Pristinamycin is being studied for its effectiveness in treating two different bacterial infections: community-acquired pneumonia in adults and tonsillitis caused by Group A Streptococcus in children and young adults aged 6 to 25 years.
  • How is Pristinamycin compared to other antibiotics in these studies? Pristinamycin is being compared to Amoxicillin in both trials. The studies aim to determine if Pristinamycin is as effective as (non-inferior to) Amoxicillin in treating these infections.
  • What are the dosages of Pristinamycin used in these trials? In the pneumonia study, adults receive 2g twice daily for 2 days, then 1g three times daily for 5 to 7 days. In the tonsillitis study, children receive 50 mg/kg/day in 2 doses, while adults receive 1g twice daily, both for 4 days.
  • How long do the clinical trials last? The pneumonia study lasts for 1 month for each patient, with a treatment period of 7 to 9 days and a follow-up period of 21 to 23 days. The tonsillitis study duration is not explicitly stated, but the final assessment is done 10 to 14 days after starting treatment.
  • What are the main outcomes these trials are measuring? The pneumonia study primarily measures the percentage of patients cured based on clinical and radiological assessments. The tonsillitis study focuses on bacterial eradication as its primary outcome. Both studies also look at safety and the occurrence of adverse events.

Ongoing Clinical Trials on Pristinamycin

  • Study on Early Stopping of Antibiotics in Elderly Patients with Viral Infections Using Amoxicillin, Clavulanic Acid, Piperacillin, Tazobactam, and Pristinamycin

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Customized Antibiotic Treatment Duration for Hospitalized Patients with Community-Acquired Pneumonia Using Cefotaxime and Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study of antibiotic combination therapy duration based on patient response for adults with community-acquired pneumonia

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Pristinamycin: An antibiotic medication used to treat various bacterial infections. In these trials, it's being studied for pneumonia and tonsillitis.
  • Amoxicillin: A common antibiotic used to treat a wide range of bacterial infections. It's being used as a comparison drug in these studies.
  • Community-acquired pneumonia: A type of lung infection that people can get in everyday life, outside of hospitals or healthcare facilities.
  • Tonsillitis: An inflammation of the tonsils, often caused by bacterial or viral infections.
  • Group A Streptococcus (GAS): A type of bacteria that can cause various infections, including tonsillitis.
  • Non-inferiority study: A type of clinical trial that aims to show that a new treatment is not worse than a standard treatment by more than a pre-specified amount.
  • Bacteriological efficacy: The ability of an antibiotic to eliminate bacteria causing an infection.
  • Procalcitonin: A protein in the blood that can be measured to help diagnose bacterial infections.
  • PORT Score: A scoring system used to assess the severity of pneumonia and guide treatment decisions.
  • Per Protocol (PP) group: A subset of study participants who completed the trial exactly as specified in the protocol.

References

  1. https://clinicaltrials.gov/study/NCT02332577
  2. https://clinicaltrials.gov/study/NCT00393744